4820 Emperor Boulevard
651 articles with IQVIA
IQVIA™ (NYSE:IQV) announces its launch of the IQVIA Patient Portal, a global web-based solution built on a leading health cloud platform.
IQVIA expects to fund the Repurchase with cash on hand and borrowings from its revolving credit facility.
IQVIA™ (NYSE:IQV) today announced that a new Life Science Strategy Group (LSSG) report named IQVIA the market leader in real world data and real world evidence services.
IQVIA™ announced that Cynthia Verst, IQVIA’s president, Design and Delivery Innovation, Research & Development Solutions, has been named to PharmaVOICE magazine’s annual list of the 100 most influential and inspiring individuals within the life sciences industry.
IQVIA Holdings Inc. announced that its wholly owned subsidiary, IQVIA Inc., priced an offering of €720,000,000 in aggregate principal amount of senior notes due 2028.
IQVIA Reports Second-Quarter 2019 Results, Raises Full-Year Revenue and Adjusted Diluted EPS Guidance
IQVIA Holdings Inc., a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry, reported financial results for the quarter ended June 30, 2019.
IQVIA Awarded Frost & Sullivan’s Life Sciences Product Leadership Award for Its Advanced Quality Management Technology Solution
IQVIA™ (NYSE:IQV) today announced it has received the Frost & Sullivan’s 2018 Global Enterprise Quality Management Solutions for Life Sciences Product Leadership award.
IQVIA Holdings Inc. (“IQVIA™”) (NYSE: IQV) has been named to the Forbes 2019 list of America’s Best Employers for Women
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), will announce its second-quarter 2019 financial results before the market opens on Wednesday, July 24, 2019.
Lannett Company, Inc. announced that it has entered into a three-year agreement with Elite Pharmaceuticals to be the exclusive U.S. distributor of a Dantrolene Capsules 25 mg, 50 mg and 100 mg.
Disruptive tech simplifies patient engagement and amplifies patients’ voices to advance outcomes for life science companies
Chiesi Group Selects IQVIA’s OCE Technology Platform to Develop a Customer Centric Ecosystem across the Organization
Leveraging innovative technology to orchestrate cross functional teamwork and multichannel interactions with external stakeholders
Clinical Ink’s Jonathan Andrus Invited to Speak at the Duke-Margolis Center for Health Policy Public Meeting
Clinical Ink is pleased to announce that Jonathan Andrus, chief business officer at Clinical Ink, has been invited to be a panelist in a public meeting hosted by the Duke-Margolis Center for Health Policy on July 17, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with the FDA, will discuss opportunities to improve the implementation of risk-based monitoring (RBM) in clinical investigations.
IQVIA’s OCE Technology Platform Selected by Zambon to Establish a Global Multichannel Commercial Engagement Model for OTC Business
Italian multinational pharmaceutical company to coordinate all physical and digital activities with pharmacists using IQVIA Technologies’ end-to-end solution.
IQVIA™ Institute for Human Data Science Releases Global Oncology Trends 2019 Study: Record Number of Cancer Drugs Launched in 2018 across 17 Indications
The IQVIA™ Institute for Human Data Science found in its latest report, Global Oncology Trends 2019: Therapeutics, Clinical Development and Health System Implications, that in 2018 a record-setting 15 new active substance oncology treatments with 17 indications, including one tissue-agnostic therapy, launched in the U.S.
IQVIA™ (NYSE:IQV) is pleased to have provided support towards the approval from the U.S. Food and Drug Administration to expand the indications for IBRANCE® (palbociclib) in combination with an aromatase inhibitor or fulvestrant to include the treatment of men with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer
IQVIA™ announced that three of the company’s women leaders have received significant awards for their leadership, vision and strategic abilities to drive disruptive technologies, improve health outcomes, and advance innovation.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), announced today that Ari Bousbib, chairman and chief executive officer, will speak at the William Blair 39th Annual Growth Stock Conference in Chicago, IL on Wednesday, June 5, 2019 at 10:40 a.m. CT / 11:40 a.m. ET.
Health Economic Model Published in Advances in Therapy Demonstrates Reduced Cost and Decreased Hospital Stay with the RECELL® System
AVITA Medical announced that the health economic model of the U.S. burn care pathway, developed in collaboration with Biomedical Advanced Research and Development Authority (BARDA) and IQVIA, has been published in the peer-reviewed journal, Advances in Therapy.
Medidata NEXT London 2019: Blending the Best of Clinical Development, AI-Enabled Platform Demonstrations and Regulatory Compliance for Leaders in Life Sciences
Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market developments